Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Articles in this Series –
- Details on Approved Cancer Targeting Antibodies. (46 Molecules)
- Monoclonal Antibodies in Active Clinical Development – Developers, Pipeline, Target & Cancer Indication. (112 Molecules)
- Monoclonal Antibodies in Active Preclinical Development – Developers, Pipeline, Target & Cancer Indication. (200 Molecules)
- Details on Approved Cancer Targeting BiSpecific Antibodies. (XX Molecules)
- Bispecific Antibodies in Active Clinical Development – Developers, Pipeline, Targets & Cancer Indication. (XX Molecules)
- Bispecific Antibodies in Active Preclinical Development – Developers, Pipeline, Targets & Cancer Indication. (XX Molecules)
- Details on Approved Cancer Targeting Antibodies Drug Conjugates. (XX Molecules)
- Antibody Drug Conjugates in Active Clinical Development – Developers, Pipeline, Targets & Cancer Indication. (XX Molecules)
- Antibody Drug Conjugates in Active Preclinical Development – Developers, Pipeline, Targets & Cancer Indication. (XX Molecules)
Cancer Targeting Antibodies in Development
Bispecific Antibodies
Bispecific (bsAbs) & Multispecific antibodies are a diverse family of antibody constructs that recognize two or more epitopes. These candidates are perfect fit as one arm binds to cancer cells, while other recruits immune cells to the right place of action. Thus, most bsAbs are bispecific T-cell-engagers (BiTEs), designed...
Discussion about this post